FDA clears a Phase III path for Biogen’s BACE drug for Alzheimer’s
Biogen has taken another step forward in prepping a Phase III program for its BACE drug for Alzheimer’s, with its partner Eisai noting that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
